摘要
三分之一的癫痫病人因抗癫痫治疗有限的疗效导致药物治疗无效。因此,去寻找更有效、安全和耐受良好的抗癫痫药物具有极大需要。大量研究结果表明腺苷(Ado)、鸟嘌呤核苷(Guo)、肌苷(Ino)或尿苷(Urd)是内源性抗癫痫调节器。此外,核苷及其衍生物或许在癫痫治疗中是安全和有效的潜在药物。相反,显示核苷水平、代谢、受体和转运蛋白的nucleosidergic调节系统可能也与癫痫病机有关。Ado受体激动剂和拮抗剂的应用、核苷水平的提升(例如,通过核苷代谢抑制剂和Ado释放植入物)或非Ado核苷的使用或许也可成为减少癫痫活动的有效方法。然而,所有药物作用于nucleosidergic调节系统可能影响由多种核苷过程密切控制的神经胶质-神经元交互的精细调节。复合体的干扰、神经元和星形胶质细胞间通过nucleosidergic调节机制的双向交流可能导致中枢神经系统(CNS)的病理改变,并且因此可能引起严重副作用。因此,对nucleosidergic调节控制神经胶质-神经元交互的深入了解为开发更为有效和安全的以核苷为基础的抗癫痫药物是至关重要的。本文集中讨论Ado和Urd在神经胶质-神经元交互中的作用,强调他们在癫痫治疗中的影响。
关键词: 癫痫治疗,神经胶质,神经元,核苷。
Current Medicinal Chemistry
Title:Effects of Nucleosides on Glia - Neuron Interactions Open up New Vistas in the Development of More Effective Antiepileptic Drugs
Volume: 22 Issue: 12
Author(s): Zsolt Kovacs, Julianna Kardos, Katalin A. Kekesi, Gabor Juhasz, Renata Lakatos and Laszlo Heja
Affiliation:
关键词: 癫痫治疗,神经胶质,神经元,核苷。
摘要: One-third of epileptic patients are drug refractory due to the limited efficacy of antiepileptic therapy. Thus, there is an immense need to find more effective, safer and well-tolerated antiepileptic drugs. A great deal of results suggests that adenosine (Ado), guanosine (Guo), inosine (Ino) or uridine (Urd) are endogenous antiepileptogenic modulators. Furthermore, nucleosides and their derivatives may be safe and effective potential drugs in the treatment of epilepsy. Conversely, nucleosidergic modulatory system implying nucleoside levels, metabolism, receptors and transporters may also be involved in seizure pathomechanisms. Application of Ado receptor agonists as well as antagonists, elevation of nucleoside levels (e.g., by nucleoside metabolism inhibitors, and Adoreleasing implants) or utilization of non-Ado nucleosides may also turn to be useful approaches to decrease epileptic activity. However, all drugs exerting their effects on the nucleosidergic modulatory system may affect the fine regulation of glia-neuron interactions that are intimately governed by various nucleosidergic processes. Perturbation of the complex, bidirectional communication between neurons and astrocytes through these nucleosidergic modulatory mechanisms may lead to pathological changes in the central nervous system (CNS) and therefore may cause significant side effects. Thus, a deeper understanding of the nucleosidergic modulatory control over glia-neuron interactions is essential in order to develop more effective and safe nucleoside-based antiepileptic drugs. In this review article we focus on the role of Ado and Urd in glia-neuron interactions, placing emphasis on their implications for the treatment of epilepsy.
Export Options
About this article
Cite this article as:
Zsolt Kovacs, Julianna Kardos, Katalin A. Kekesi, Gabor Juhasz, Renata Lakatos and Laszlo Heja , Effects of Nucleosides on Glia - Neuron Interactions Open up New Vistas in the Development of More Effective Antiepileptic Drugs, Current Medicinal Chemistry 2015; 22 (12) . https://dx.doi.org/10.2174/0929867322666150212153210
DOI https://dx.doi.org/10.2174/0929867322666150212153210 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
QSAR Modeling of Histamine H3R Antagonists/inverse Agonists as Future Drugs for Neurodegenerative Diseases
Current Neuropharmacology Emerging Synergisms Between Drugs and Physiologically-Patterned Weak Magnetic Fields: Implications for Neuropharmacology and the Human Population in the Twenty-First Century
Current Neuropharmacology Cerebroprotective Functions of HO-2
Current Pharmaceutical Design Ultrasound-promoted Organic Synthesis - A Recent Update
Current Organic Chemistry A Comprehensive Review on Preclinical Evidence-based Neuroprotective Potential of <i>Bacopa monnieri</i> against Parkinson's Disease
Current Drug Targets The Hippocampal Autophagic Machinery is Depressed in the Absence of the Circadian Clock Protein PER1 that may Lead to Vulnerability During Cerebral Ischemia
Current Neurovascular Research Neuropharmacological Profile of Gamma-Decanolactone on Chemically-induced Seizure in Mice
Central Nervous System Agents in Medicinal Chemistry Plasma Phospholipids are Associated with Mild Cognitive Impairment in Type 2 Diabetic Patients
Current Alzheimer Research Population Pharmacokinetics of Levetiracetam: A Systematic Review
Current Reviews in Clinical and Experimental Pharmacology Protective Mechanisms of Helminths Against Reactive Oxygen Species are Highly Promising Drug Targets
Current Medicinal Chemistry Valproic Acid Metabolism and its Consequences on Sexual Functions
Current Drug Metabolism Intracellular and Extracellular Zinc Detection by Organic Fluorescent Receptor
Current Organic Chemistry Cell-based Treatment of Cerebral Palsy: Still a Long Way Ahead
Current Stem Cell Research & Therapy The Therapeutic Potential of Melatonin in Neurological Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Effects of Chronic Lamotrigine Administration on Maximal Electroshock- Induced Seizures in Mice
CNS & Neurological Disorders - Drug Targets Preface [Hot Topic: Rational Drug Design and The Discovery of the 1,2,3-Triazolines as a Unique Class of Anticonvulsants and Antiischemic Agents (Guest Editor: Pankaja K. Kadaba)]
Current Medicinal Chemistry Potential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders
Current Pharmaceutical Design Translocator Protein Ligands as Promising Therapeutic Tools for Anxiety Disorders
Current Medicinal Chemistry Comparative Studies on Phospholipase A2 as a Marker for Gut Microbiota- liver-brain Axis in a rodent Model of Autism
Current Proteomics Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis
CNS & Neurological Disorders - Drug Targets